From: Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
Days from HSCT | Clinical condition/therapeutic intervention |
---|---|
0 | HSCT |
17 | Neutrophil recovery |
19 | Platelet recovery |
22 | aGvHD onset: diarrhea (st.I) and skin (st.II). Started PDN-equivalent 2Â mg/kg/iv |
28 | Diarrhea exceeded 1500Â mL/day (st.III) and started budesonide 3Â mg tid po |
29 | Diarrhea exceeded 2000Â mL/day (st.IV) and started MMF 1Â g tid iv |
33 | EGDS with biopsies (GvHD confirmation). Started Ruxolitinib 5Â mg bid |
36 | Steroid taper |
39 | Diarrhea below 1000 mL and Ruxolitinib 5 + 10 mg/day. Stop MMF |
45 | Resumed oral food intake |
49 | Switch to oral CsA |
54 | EGDS with biopsies: no signs of GvHD |
61 | Switch PDN po |
66 | Reduced Ruxolitinib to 5Â mg bid |
70 | Patient discharged |
100 | Reduced Ruxolitinib to 5Â mg/day |
135 | Steroid stopped |
156 | Ruxolitinib stopped |